Mark W. J. Strachan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark W. J. Strachan has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Rebecca M. Reynolds
Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
4 shared publications Brian M. Frier
Department of Diabetes, Royal Infirmary of Edinburgh, Edinburgh, UK
2 shared publicationsJacqueline F. Price
Public Health Sciences Community, University of Edinburgh, Edinburgh, UK
2 shared publicationsRory J. Mitchell
Public Health Sciences Community, University of Edinburgh, Edinburgh, UK
2 shared publicationsAlan W Patrick
Department of Endocrinology, Royal Infirmary of Edinburgh, Edinburgh, UK
1 shared publication- Amanda J. Lee
Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
1 shared publication
Latest Publications
- 15 April 2009
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (5) , 407-414
The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies
Dementia is becoming increasingly common in western societies and carries with it a substantial clinical, social and economic burden. It is now well established that type 2 diabetes is a risk factor for dementia and it is likely that this association has a multifactorial aetiology. There is a relative paucity of data on interventions to improve cognitive function in people with type 2 diabetes. Two small randomized controlled trials have suggested that better glycaemic control, over a relatively short time period, can improve or prevent decline in cognitive function. There is also increasing interest in the link between intracerebral insulin and cognitive impairment. Several studies have suggested that relative and/or absolute deficiency of insulin may occur in Alzheimer’s dementia and, although one small randomized trial was essentially negative, randomized trials are currently underway to investigate the impact of thiazolidinediones on cognitive function in dementia. The hypothalamic–pituitary–adrenal axis is also activated in people with type 2 diabetes and there are data linking increased cortisol concentrations with cognitive impairment. Inhibition of the 11 β‐hydroxysteroid dehydrogenase type 1 enzyme, which generates cortisol from inactive cortisone in many tissues including the brain, is an attractive therapeutic target to enhance cognition. Large‐scale epidemiological and intervention studies are now underway, which should enhance our understanding and management of cognitive impairment in type 2 diabetes.
- 15 April 2009
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (5) , 407-414
The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies
Dementia is becoming increasingly common in western societies and carries with it a substantial clinical, social and economic burden. It is now well established that type 2 diabetes is a risk factor for dementia and it is likely that this association has a multifactorial aetiology. There is a relative paucity of data on interventions to improve cognitive function in people with type 2 diabetes. Two small randomized controlled trials have suggested that better glycaemic control, over a relatively short time period, can improve or prevent decline in cognitive function. There is also increasing interest in the link between intracerebral insulin and cognitive impairment. Several studies have suggested that relative and/or absolute deficiency of insulin may occur in Alzheimer’s dementia and, although one small randomized trial was essentially negative, randomized trials are currently underway to investigate the impact of thiazolidinediones on cognitive function in dementia. The hypothalamic–pituitary–adrenal axis is also activated in people with type 2 diabetes and there are data linking increased cortisol concentrations with cognitive impairment. Inhibition of the 11 β‐hydroxysteroid dehydrogenase type 1 enzyme, which generates cortisol from inactive cortisone in many tissues including the brain, is an attractive therapeutic target to enhance cognition. Large‐scale epidemiological and intervention studies are now underway, which should enhance our understanding and management of cognitive impairment in type 2 diabetes.
- Open Access
- 11 December 2008
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 8 (1) , 18
The Edinburgh Type 2 Diabetes Study: study protocol
Risk factors underlying the development and progression of some of the less well-recognised complications of type 2 diabetes, including cognitive impairment and non-alcoholic fatty liver disease, are poorly understood. The Edinburgh Type 2 Diabetes Study was established in 2006 in order to investigate the role of potential risk factors in these complications, as well as to further investigate mechanisms underlying the development and progression of micro and macrovascular disease in type 2 diabetes. The study is designed as a prospective cohort study. Participants recruited at baseline (2006–2007) constitute 1066 men and women aged 60 to 75 years with established type 2 diabetes, living in the Lothian region of central Scotland. Subjects underwent detailed cognitive and physical examination, the latter including measures of micro- and macro-vascular disease, glycaemic control, body fat composition and plasma inflammatory markers, cortisol, lipids and liver function tests. Participants were re-examined after one year with hepatic ultrasonography and additional measures of vascular disease. This paper reports the methods of recruitment to the study and examinations performed at baseline and one year. Follow-up cognitive, vascular and liver assessments are scheduled for 2010–2011 when subjects will have been in the study for 4 years. This study will provide a wealth of epidemiological and biomarker data that should be invaluable in the identification of potentially modifiable, causal risk factors for diabetes-related cognitive impairment, liver dysfunction and vascular disease, which can be targeted for the development of preventive and therapeutic interventions.
- 11 December 2008
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 8 (1) , 18
Open AccessThe Edinburgh Type 2 Diabetes Study: study protocol
Risk factors underlying the development and progression of some of the less well-recognised complications of type 2 diabetes, including cognitive impairment and non-alcoholic fatty liver disease, are poorly understood. The Edinburgh Type 2 Diabetes Study was established in 2006 in order to investigate the role of potential risk factors in these complications, as well as to further investigate mechanisms underlying the development and progression of micro and macrovascular disease in type 2 diabetes. The study is designed as a prospective cohort study. Participants recruited at baseline (2006–2007) constitute 1066 men and women aged 60 to 75 years with established type 2 diabetes, living in the Lothian region of central Scotland. Subjects underwent detailed cognitive and physical examination, the latter including measures of micro- and macro-vascular disease, glycaemic control, body fat composition and plasma inflammatory markers, cortisol, lipids and liver function tests. Participants were re-examined after one year with hepatic ultrasonography and additional measures of vascular disease. This paper reports the methods of recruitment to the study and examinations performed at baseline and one year. Follow-up cognitive, vascular and liver assessments are scheduled for 2010–2011 when subjects will have been in the study for 4 years. This study will provide a wealth of epidemiological and biomarker data that should be invaluable in the identification of potentially modifiable, causal risk factors for diabetes-related cognitive impairment, liver dysfunction and vascular disease, which can be targeted for the development of preventive and therapeutic interventions.
- Open Access
- 23 November 2008
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 88 (1) , 131-146
The relationship between type 2 diabetes and dementia
The prevalence of type 2 diabetes and dementia are set to rise inexorably over the next 30–40 years. There are now substantial data to suggest that type 2 diabetes is associated with an increased risk of dementia. This is a narrative review using data from individual studies and review articles known to the authors. A Medline search was also undertaken and reference lists were reviewed to identify additional relevant studies. Type 2 diabetes is associated with an increased risk of both Alzheimer's and Vascular dementia, although the reality is that many affected individuals have mixed forms of dementia. The mechanisms underpinning this association remain to be clearly delineated. Type 2 diabetes is a complex disorder and so it is likely that multiple different, synergistic processes may interact to promote cognitive decrements. Recent data suggest that glucocorticoids excess and elevated inflammatory markers may also have a role in the aetiology of diabetes-related cognitive impairment. Large-scale, prospective epidemiological studies are now required to accurately delineate the pathogenesis of cognitive impairment in people with type 2 diabetes. These are underway and randomized trials of diabetes-specific interventions are also starting to include cognitive function as an outcome measure.
- 23 November 2008
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 88 (1) , 131-146
Open AccessThe relationship between type 2 diabetes and dementia
The prevalence of type 2 diabetes and dementia are set to rise inexorably over the next 30–40 years. There are now substantial data to suggest that type 2 diabetes is associated with an increased risk of dementia. This is a narrative review using data from individual studies and review articles known to the authors. A Medline search was also undertaken and reference lists were reviewed to identify additional relevant studies. Type 2 diabetes is associated with an increased risk of both Alzheimer's and Vascular dementia, although the reality is that many affected individuals have mixed forms of dementia. The mechanisms underpinning this association remain to be clearly delineated. Type 2 diabetes is a complex disorder and so it is likely that multiple different, synergistic processes may interact to promote cognitive decrements. Recent data suggest that glucocorticoids excess and elevated inflammatory markers may also have a role in the aetiology of diabetes-related cognitive impairment. Large-scale, prospective epidemiological studies are now required to accurately delineate the pathogenesis of cognitive impairment in people with type 2 diabetes. These are underway and randomized trials of diabetes-specific interventions are also starting to include cognitive function as an outcome measure.
- 1 September 2008
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 8 (5) , 236-240
Clinical variables associated with non-dipping of nocturnal blood pressure in type 2 diabetes
Aim Non-dipping of nocturnal BP (blood pressure) is common in people with type 2 diabetes and is associated with increased risk of cardiovascular morbidity and mortality. This study aimed to identify the factors associated with nocturnal non-dipping of BP in people with type 2 diabetes. Methods Data were examined from 100 people with type 2 diabetes who had undergone ambulatory BP monitoring. Dippers were defined as those with a systolic night-time BP dip over 15%, and non-dippers as those with a systolic night-time BP dip of under 5%. Results There was no significant difference between the mean awake systolic BP in the dipping (142.9 mmHg) and the non-dipping (142.0 mmHg) groups (p=0.77). Non-dippers were significantly older (p Conclusion Albuminuria is strongly associated with non-dipping of nocturnal BP in people with type 2 diabetes.
- 1 September 2008
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 8 (5) , 236-240
Clinical variables associated with non-dipping of nocturnal blood pressure in type 2 diabetes
Aim Non-dipping of nocturnal BP (blood pressure) is common in people with type 2 diabetes and is associated with increased risk of cardiovascular morbidity and mortality. This study aimed to identify the factors associated with nocturnal non-dipping of BP in people with type 2 diabetes. Methods Data were examined from 100 people with type 2 diabetes who had undergone ambulatory BP monitoring. Dippers were defined as those with a systolic night-time BP dip over 15%, and non-dippers as those with a systolic night-time BP dip of under 5%. Results There was no significant difference between the mean awake systolic BP in the dipping (142.9 mmHg) and the non-dipping (142.0 mmHg) groups (p=0.77). Non-dippers were significantly older (p Conclusion Albuminuria is strongly associated with non-dipping of nocturnal BP in people with type 2 diabetes.
Diabetes, cognitive impairment, and dementia
Footnotes Competing interests: All authors are grant holders for the ET2DS, a substudy of which is supported by Pfizer. MWJS has received consultancy fees, fees for speaking, and reimbursement for attending a symposium from GlaxoSmithKline (GSK), manufacturers of rosiglitazone. MWJS also sits on a GSK independent data monitoring committee. MWJS has received funds to support staff members from other companies that make drugs for diabetes—Takeda, Pfizer, and Sanofi Aventis. JFP has received research funding from Bayer Healthcare. BMF has received research funding, consultancy fees, and honorariums for lectures from Eli Lilly, Takeda, GSK, Sanofi-Aventis, and Novo Nordisk. Provenance and peer review: Not commissioned; externally peer reviewed.
Diabetes, cognitive impairment, and dementia
Footnotes Competing interests: All authors are grant holders for the ET2DS, a substudy of which is supported by Pfizer. MWJS has received consultancy fees, fees for speaking, and reimbursement for attending a symposium from GlaxoSmithKline (GSK), manufacturers of rosiglitazone. MWJS also sits on a GSK independent data monitoring committee. MWJS has received funds to support staff members from other companies that make drugs for diabetes—Takeda, Pfizer, and Sanofi Aventis. JFP has received research funding from Bayer Healthcare. BMF has received research funding, consultancy fees, and honorariums for lectures from Eli Lilly, Takeda, GSK, Sanofi-Aventis, and Novo Nordisk. Provenance and peer review: Not commissioned; externally peer reviewed.
- 17 August 2007
- Published by Wiley
- p. 49-81
Frequency, Causes and Risk Factors for Hypoglycaemia in Type 1 Diabetes
- 17 August 2007
- Published by Wiley
- p. 49-81
Frequency, Causes and Risk Factors for Hypoglycaemia in Type 1 Diabetes
- 5 July 2007
- Published by Wiley in The Journal of Physiology
- Vol. 582 (2) , 475-476
Physiological responses to hypoglycaemia - not all ‘just in the head'
- 5 July 2007
- Published by Wiley in The Journal of Physiology
- Vol. 582 (2) , 475-476
Physiological responses to hypoglycaemia - not all ‘just in the head'
- 1 April 2007
- Published by Wiley in Diabetic Medicine
- Vol. 24 (4) , 359-363
Does an Integrated Care Pathway enhance the management of diabetic ketoacidosis?
Integrated Care Pathways (ICPs) are management plans that indicate the sequence and timing of the optimal treatment for individuals with a given disorder. The treatment of diabetic ketoacidosis (DKA) before and after the implementation of an ICP in a teaching hospital was examined. Twenty-seven episodes of DKA were identified during the 13-month control period and 22 in the 13 months following implementation of the ICP. Case notes were reviewed and relevant clinical data extracted. The introduction of the ICP was associated with a reduction in the time taken to initiate intravenous fluid [45.0 (5-225) min to 37.5 (0-135) min; P = 0.01]. Time taken to initiate insulin infusion was also reduced [60.0 (5-755) min to 37.5 (0-175) min; P = 0.02]. The proportion of patients commenced on intravenous insulin within 60 min increased from 48 to 77% (P = 0.04). In addition, there was a reduction in the prescription of antibiotics (48-18%; P = 0.028) and low molecular weight heparin (59-5%; P < 0.001). Length of stay was not affected. The ICP significantly improved key areas in the management of DKA, although there remains room for further improvements.
- 1 April 2007
- Published by Wiley in Diabetic Medicine
- Vol. 24 (4) , 359-363
Does an Integrated Care Pathway enhance the management of diabetic ketoacidosis?
Integrated Care Pathways (ICPs) are management plans that indicate the sequence and timing of the optimal treatment for individuals with a given disorder. The treatment of diabetic ketoacidosis (DKA) before and after the implementation of an ICP in a teaching hospital was examined. Twenty-seven episodes of DKA were identified during the 13-month control period and 22 in the 13 months following implementation of the ICP. Case notes were reviewed and relevant clinical data extracted. The introduction of the ICP was associated with a reduction in the time taken to initiate intravenous fluid [45.0 (5-225) min to 37.5 (0-135) min; P = 0.01]. Time taken to initiate insulin infusion was also reduced [60.0 (5-755) min to 37.5 (0-175) min; P = 0.02]. The proportion of patients commenced on intravenous insulin within 60 min increased from 48 to 77% (P = 0.04). In addition, there was a reduction in the prescription of antibiotics (48-18%; P = 0.028) and low molecular weight heparin (59-5%; P < 0.001). Length of stay was not affected. The ICP significantly improved key areas in the management of DKA, although there remains room for further improvements.
- 26 October 2005
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 33 (5) , 1037-1040
Insulin and cognitive function in humans: experimental data and therapeutic considerations
Data from experimental studies in animals and from epidemiological studies in humans suggest a link between insulin and cognitive performance. Do these results translate into clinical and therapeutic benefit for people with cognitive impairment? Insulin injected peripherally can readily cross the blood–brain barrier. Intravenous insulin can improve aspects of cognitive function in healthy adults and in individuals with Alzheimer's dementia. Moreover, intravenous insulin increases concentrations of a long form of β-amyloid protein, Aβ42. One potential confounding factor with these data, however, is the need for co-administration of glucose with the insulin to maintain euglycaemia as glucose itself can facilitate memory function. Administration of insulin via the intranasal route is scientifically (and therapeutically) more attractive because the insulin goes directly to the cerebrospinal fluid, with minimal systemic absorption; this obviates the need for a glucose infusion. Intranasal insulin may improve some aspects of memory in healthy individuals, but has yet to be studied in people with cognitive impairment. TZDs (thiazolidinediones) reduce peripheral insulin concentrations by enhancing insulin sensitivity. In adults with Type II (non-insulin-dependent) diabetes, TZD therapy improves memory function, but so does sulphonylurea therapy (which elevates peripheral insulin concentrations). Improved memory is linked to lower blood glucose concentrations, rather than altered insulin levels. However, major trials are currently under way examining the impact of TZDs in people with dementia.
- 26 October 2005
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 33 (5) , 1037-1040
Insulin and cognitive function in humans: experimental data and therapeutic considerations
Data from experimental studies in animals and from epidemiological studies in humans suggest a link between insulin and cognitive performance. Do these results translate into clinical and therapeutic benefit for people with cognitive impairment? Insulin injected peripherally can readily cross the blood–brain barrier. Intravenous insulin can improve aspects of cognitive function in healthy adults and in individuals with Alzheimer's dementia. Moreover, intravenous insulin increases concentrations of a long form of β-amyloid protein, Aβ42. One potential confounding factor with these data, however, is the need for co-administration of glucose with the insulin to maintain euglycaemia as glucose itself can facilitate memory function. Administration of insulin via the intranasal route is scientifically (and therapeutically) more attractive because the insulin goes directly to the cerebrospinal fluid, with minimal systemic absorption; this obviates the need for a glucose infusion. Intranasal insulin may improve some aspects of memory in healthy individuals, but has yet to be studied in people with cognitive impairment. TZDs (thiazolidinediones) reduce peripheral insulin concentrations by enhancing insulin sensitivity. In adults with Type II (non-insulin-dependent) diabetes, TZD therapy improves memory function, but so does sulphonylurea therapy (which elevates peripheral insulin concentrations). Improved memory is linked to lower blood glucose concentrations, rather than altered insulin levels. However, major trials are currently under way examining the impact of TZDs in people with dementia.
- 1 October 2005
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 33 (5) , 1037-40
Insulin and cognitive function in humans: experimental data and therapeutic considerations
Data from experimental studies in animals and from epidemiological studies in humans suggest a link between insulin and cognitive performance. Do these results translate into clinical and therapeutic benefit for people with cognitive impairment? Insulin injected peripherally can readily cross the blood-brain barrier. Intravenous insulin can improve aspects of cognitive function in healthy adults and in individuals with Alzheimer's dementia. Moreover, intravenous insulin increases concentrations of a long form of beta-amyloid protein, Abeta42. One potential confounding factor with these data, however, is the need for co-administration of glucose with the insulin to maintain euglycaemia as glucose itself can facilitate memory function. Administration of insulin via the intranasal route is scientifically (and therapeutically) more attractive because the insulin goes directly to the cerebrospinal fluid, with minimal systemic absorption; this obviates the need for a glucose infusion. Intranasal insulin may improve some aspects of memory in healthy individuals, but has yet to be studied in people with cognitive impairment. TZDs (thiazolidinediones) reduce peripheral insulin concentrations by enhancing insulin sensitivity. In adults with Type II (non-insulin-dependent) diabetes, TZD therapy improves memory function, but so does sulphonylurea therapy (which elevates peripheral insulin concentrations). Improved memory is linked to lower blood glucose concentrations, rather than altered insulin levels. However, major trials are currently under way examining the impact of TZDs in people with dementia.
- 1 October 2005
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 33 (5) , 1037-40
Insulin and cognitive function in humans: experimental data and therapeutic considerations
Data from experimental studies in animals and from epidemiological studies in humans suggest a link between insulin and cognitive performance. Do these results translate into clinical and therapeutic benefit for people with cognitive impairment? Insulin injected peripherally can readily cross the blood-brain barrier. Intravenous insulin can improve aspects of cognitive function in healthy adults and in individuals with Alzheimer's dementia. Moreover, intravenous insulin increases concentrations of a long form of beta-amyloid protein, Abeta42. One potential confounding factor with these data, however, is the need for co-administration of glucose with the insulin to maintain euglycaemia as glucose itself can facilitate memory function. Administration of insulin via the intranasal route is scientifically (and therapeutically) more attractive because the insulin goes directly to the cerebrospinal fluid, with minimal systemic absorption; this obviates the need for a glucose infusion. Intranasal insulin may improve some aspects of memory in healthy individuals, but has yet to be studied in people with cognitive impairment. TZDs (thiazolidinediones) reduce peripheral insulin concentrations by enhancing insulin sensitivity. In adults with Type II (non-insulin-dependent) diabetes, TZD therapy improves memory function, but so does sulphonylurea therapy (which elevates peripheral insulin concentrations). Improved memory is linked to lower blood glucose concentrations, rather than altered insulin levels. However, major trials are currently under way examining the impact of TZDs in people with dementia.